<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">Coronary heart disease</z:e> is still the leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> in industrialized nations, occurring either as <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0151814" disease_type="Disease or Syndrome" abbrv="">coronary occlusion</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or as <z:hpo ids='HP_0011010'>chronic</z:hpo> ischaemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> caused by continuous obstruction of one or more coronary arteries </plain></SENT>
<SENT sid="1" pm="."><plain>Even after successful reperfusion, an additional loss of otherwise vital cardiomyocytes may occur in the primary ischaemic area, called lethal reperfusion injury </plain></SENT>
<SENT sid="2" pm="."><plain>In experimental settings, delivery of therapeutic agents targeting the reperfusion injury reduces the <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 30% </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to the choice of therapeutic agent and time point, the mode of application may be crucial for the therapeutic success </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, this review focuses on the current and future administration techniques for early and late post-<z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> therapies </plain></SENT>
</text></document>